Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

Ida Azizkhanian, Olgica Trenchevska, Yara Bashawri, Jiaqi Hu, Juraj Koska, Peter D. Reaven, Randall W. Nelson, Dobrin Nedelkov, Hussein N. Yassine

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)808-815
Number of pages8
JournalJournal of Clinical Lipidology
Issue number4
StatePublished - Jul 1 2016


  • Apolipoprotein A-II
  • Diabetes
  • Mass spectrometry
  • Oxidations

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes'. Together they form a unique fingerprint.

Cite this